Montek (Pertechnetate (99mtc) Sodium)

Sodium pertechnetate, the active ingredient in Montek, is a radiopharmaceutical presented as an injectable solution for intravenous and ocular use. It emits gamma radiation that localizes in specific tissues, enabling diagnostic visualization in nuclear medicine procedures.

GNH USA supplies Montek as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies, diagnostic imaging centres and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for cross‑border distribution, ensuring reliable access to this essential imaging agent for clinical teams worldwide.

Montek is employed in nuclear medicine to visualize organ function and perfusion across several clinical pathways.

Thyroid imaging: enables functional assessment of thyroid tissue and detection of nodules or hyperfunction. Cardiac perfusion imaging: visualizes myocardial blood flow to evaluate coronary artery disease. Brain perfusion studies: assesses cerebral blood flow for stroke and epilepsy evaluation. Renal scintigraphy: evaluates renal plasma flow and differential function of kidneys.

Sodium pertechnetate may cause a range of reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain: mild discomfort at the site of administration. - Nausea: transient feeling of queasiness. - Flushing: brief warmth or redness of the skin.

Serious or Rare Side Effects: - Allergic reaction: hives, swelling, or anaphylaxis requiring immediate medical attention. - Radiation‑induced tissue injury: localized damage in high‑uptake organs. - Severe hypotension: sudden drop in blood pressure post‑injection.

When using Montek, several safety considerations should be observed to protect patients and staff. - Pregnancy: avoid unless the diagnostic benefit outweighs potential fetal radiation exposure. - Breastfeeding: discontinue nursing for an appropriate interval after administration. - Renal impairment: assess renal function as reduced clearance may affect biodistribution. - Concurrent radiopharmaceuticals: do not administer other nuclear agents within 24 hours to prevent interference. - Radiation safety: follow ALARA principles, use shielding and limit exposure time for personnel. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Sodium pertechnetate can interact with certain substances that may alter its distribution or increase radiation exposure.

Major Interactions (Avoid): - Iodine‑containing contrast agents: compete for uptake in thyroid and salivary glands, reducing image quality. - Thyroid hormone therapy: may modify tracer accumulation, affecting diagnostic interpretation.

Moderate Interactions (Monitor Closely): - Beta‑blockers: can affect cardiac perfusion imaging results. - Chemotherapeutic agents: may increase radiation sensitivity of tissues. - Other radiopharmaceuticals: simultaneous use can lead to competitive binding and inaccurate scans.